WALTHAM, Mass.–(BUSINESS WIRE)–NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Kenneth J. Snow, M.D. as Chief Medical Officer. The appointment was effective October 3, 2011.
“His intellect, natural curiosity, and experience will be invaluable as he leads our diabetes focused clinical programs.”
As Chief Medical Officer, Dr. Snow will be responsible for developing and managing the Company’s diabetes related clinical programs. These include studies to further validate the clinical and economic benefits of NC-stat® DPNCheck™ testing and various clinical and R&D activities in support of new diabetic neuropathy focused products in early development
Dr. Snow has extensive experience in diabetes, including patient care, strategic initiatives, and clinical research. Dr. Snow has spent the past 17 years at the Joslin Diabetes Center in Boston, MA. The Joslin Diabetes Center is affiliated with Harvard Medical School and is the world’s oldest and most respected diabetes care facility. Most recently, Dr. Snow was Director of Medical Programs at the Joslin Center for Strategic Initiatives. Prior to that he was Acting Chief of the Adult Diabetes Section at the Joslin. Dr. Snow also holds an appointment as Assistant Professor of Medicine at Harvard Medical School. Dr. Snow has a B.S. in Chemistry from the Massachusetts Institute of Technology, and an M.D. from Johns Hopkins School of Medicine. He completed his internship and residency at Northwestern Memorial Hospitals, Chicago, IL and fellowship training in Endocrinology at New England Medical Center Hospitals, Boston, MA. In addition to his medical training, Dr. Snow has an MBA from the Isenberg School of Business at the University of Massachusetts, Amherst.
“I am truly delighted to be joining the team at NeuroMetrix. My career has been focused on improving the lives of people with diabetes and I believe that this opportunity allows me to continue in that focus. Too many patients with diabetes suffer with neuropathy. I believe that NC-stat DPNCheck will lead to better care and outcomes for people with diabetes,” said Dr. Snow.
“We are very pleased that Dr. Snow is joining NeuroMetrix as Chief Medical Officer. His deep clinical and strategic perspective on diabetes care aligns to our focus on the development and marketing of products to diagnose, monitor, and treat diabetic neuropathy which is one of the most common and devastating complications of diabetes,” said Shai N. Gozani M.D., PhD., President and Chief Executive Officer of NeuroMetrix. “His intellect, natural curiosity, and experience will be invaluable as he leads our diabetes focused clinical programs.”
NeuroMetrix is a science-based health care company improving patient care through neurotechnology. The company develops and markets innovative products for the detection, diagnosis, and monitoring of peripheral nerve disorders such as those associated with diabetes and carpal tunnel syndrome. For more information, please visit http://www.neurometrix.com.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer